Literature DB >> 15760313

Efficacy of hyoscine-N-butyl bromide (Buscopan) suppositories as a cervical spasmolytic agent in labour.

Daya Sirohiwal1, Krishna Dahiya, Mandira De.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of hyoscine-N-butyl bromide (Buscopan) suppositories in the active phase of labour, i.e. once the labour is established.
METHODS: A non-randomised controlled prospective study was carried out on 200 women in labour. In the active phase of labour, at 3 cm or more cervical dilatation, 100 women were administered Buscopan via suppository and 100 women (control) were not given any drug.
RESULTS: The duration of first stage of labour was 123.86 +/- 68.89 (mean(+)-standard deviation) minutes in the study group and 368.05 +/- 133.0 min in the control group. These differences were statistically significant. There were no differences in the duration of the second and third stages of labour. There was no increased incidence of operative deliveries in the study group. No adverse effects were noted on the mother or fetus.
CONCLUSION: Hyoscine-N-butyl bromide (HBB, Buscopan) suppositories were highly effective in shortening the duration of the first stage of labour.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15760313     DOI: 10.1111/j.1479-828X.2005.00359.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  11 in total

Review 1.  Antispasmodics for labour.

Authors:  Anke C Rohwer; Oswell Khondowe; Taryn Young
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

2.  Hyoscine N-Butylbromide for Preventing Propofol Injection Pain: A Randomized, Placebo-Controlled and Double-Blind Study.

Authors:  Mehmet Sargın; Mehmet Selçuk Uluer; Eyüp Aydoğan
Journal:  Med Princ Pract       Date:  2018-01-23       Impact factor: 1.927

3.  Effect of hyoscine butylbromide first stage of labour in multiparus women.

Authors:  L Sekhavat; S A Karbasi; R Fallah; M Mirowliai
Journal:  Afr Health Sci       Date:  2012-12       Impact factor: 0.927

4.  Diclofenac Potassium Alone Versus Diclofenac Potassium with Hyoscine-N-butyl Bromide (HBB) in Reduction of Pain in Women Undergoing Office Hysteroscopy: A Double Blind Randomized, Placebo-Controlled Trial.

Authors:  Ahmed S S A Rashwan; Mahmoud Alalfy; Sarah Aboubakr Elkomaty; Omneya Mostafa Helal; Eman Aly Hussein
Journal:  J Obstet Gynaecol India       Date:  2022-04-13

5.  Effect of hyoscine-N-butyl bromide rectal suppository on labor progress in primigravid women: randomized double-blind placebo-controlled clinical trial.

Authors:  Somayeh Makvandi; Mitra Tadayon; Mohammadreza Abbaspour
Journal:  Croat Med J       Date:  2011-04-15       Impact factor: 1.351

6.  The effect of hyoscine butylbromide in shortening the first stage of labor: A double blind, randomized, controlled, clinical trial.

Authors:  Nourah H Al Qahtani; Fatma Al Hajeri
Journal:  Ther Clin Risk Manag       Date:  2011-12-08       Impact factor: 2.423

7.  Effect of Piroxicam on ART Outcome: A Pilot Study.

Authors:  Farnaz Sohrabvand; Fedyeh Haghollahi; Masoomeh Maasomi; Mamak Shariat
Journal:  Int J Fertil Steril       Date:  2014-11-01

8.  Assessing the efficacy of vaginal hyoscine butyl bromide on cervical ripening prior to intrauterine procedures: A double-blinded clinical trial.

Authors:  Shiva Hadadian; Masoumeh Fallahian
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-11

9.  "We know it's labour pain, so we don't do anything": healthcare provider's knowledge and attitudes regarding the provision of pain relief during labour and after childbirth.

Authors:  Mary McCauley; Valentina Actis Danna; Dorah Mrema; Nynke van den Broek
Journal:  BMC Pregnancy Childbirth       Date:  2018-11-14       Impact factor: 3.007

10.  Immediate dilation of a tight or stenotic cervix by intra-procedural administration of hyoscine butylbromide: A clinical trial.

Authors:  Shiva Hadadianpour; Shahrzad Tavana; Anahita Tavana; Masoumeh Fallahian
Journal:  Int J Reprod Biomed       Date:  2019-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.